New Data Shows Mono-Iodoacetate Model as a High-Throughput Screening Tool for Osteoarthritis
July 2, 2012- Affecting nearly one-third of all adults, osteoarthritis (OA) is among the most common health problems in the United States. This leading cause of debility is characterized by degeneration of joint cartilage, synovitis, remodeling of subchondral bone, muscle weakness and musculoskeletal pain/stiffness.
Charles River Surgical Services offers a mono-iodoacetate (MIA) model of OA in the CD rat [Crl:CD(SD)]. This model is produced by a single injection of mono-iodoacetate into the knee joint. MIA inhibits glyceraldehyde-3-phosphate dehydrogenase activity in chondrocytes, resulting in disruption of glycolysis and eventual cell death. The progressive loss of chondrocytes results in histological and morphological changes in the articular cartilage, closely resembling osteoarthritis seen in humans.
This rat model uses a standard dose, resulting in a consistent OA model with mild clinical symptoms, which allows for shipping without affecting the model’s integrity.
Figure 1: Post-procedural analysis of the MIA rat model showing response to Celecoxib (trade name: Celebrex), a non-steroidal anti-inflammatory (NSAID) drug. The test was performed using a standard, commercially available grip force measurement system. This figure reflects five groups (n=16) with grip force shown on the y-axis and dose on the x-axis. Animals were tested 3 weeks post-injection. The graph depicts normal grip force in the naïve (N) animals with no knee-joint injection, a grip force deficit in the vehicle (V) group that received knee-joint injections, and a dose-related response in the knee-joint injected animals receiving the Celecoxib.
For more information on our Osteoarthritis model as well as other neuropathic models, please contact us at email@example.com.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
Selecting the appropriate animal model for your studies is critical to the success of your research. This is why, in 2011, our Model Evaluation Program was created to offer researchers a risk-free opportunity to evaluate the quality of our animal models prior to allocating valuable budget money or study resources.
Now, to further support your research needs, we have expanded our program to include the option to evaluate both surgically altered models and rodent biospecimen products
Charles River offers animal models with combined surgeries or services (e.g., feeding studies with tissue collection) to help meet the dynamic needs of our customers.
juin 10–juin 13
Visit us in booth #091 to learn more about our recent innovations including expanded diagnostic capabilities, a new online portal connecting clients with their colonies and a deep-rooted commitment to humane care.
mai 21–mai 24
RDD Europe 2013 is a forum for pulmonary and nasal drug delivery experts from all around the world to exchange scientific knowledge and expertise.
mai 23–mai 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
Charles River Laboratories, Inc.